Premium
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
At Metageno-mi, we are cre-at-ing poten-tial-ly cura-tive ther-a-peu-tics using our metage--nomics-pow-ered genome edit-ing toolbox.We believe tools with capa-bil-i-ties that go beyond the cur-rent tech-nol-o-gy land-scape will be required in order to reach the full ther-a-peu-tic poten-tial of geno... At Metageno-mi, we are cre-at-ing poten-tial-ly cura-tive ther-a-peu-tics using our metage--nomics-pow-ered genome edit-ing toolbox.We believe tools with capa-bil-i-ties that go beyond the cur-rent tech-nol-o-gy land-scape will be required in order to reach the full ther-a-peu-tic poten-tial of genome edit-ing. By har-ness-ing the pow-er of metage-nomics, the study of genomes recov-ered from uncul-ti-vat-ed organ-isms in the nat-ur-al envi-ron-ment, we are dis-cov-er-ing and devel-op-ing a suite of nov-el genome edit-ing tools with the poten-tial to make any desired ther-a-peu-tic gene edit, any-where in the human genome. Show more
MGX-001, utilizing a highly specific and efficient MG29-1 nuclease, exhibits no identifiable off-target editing MG29-1 nuclease targeting the albumin safe harbor locus showed no evidence of...
Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman primate (NHP) study through more than sixteen months of follow up MGX-001 bioengineered FVIII...
The Gross Law Firm Notifies Metagenomi, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MGX PR Newswire NEW YORK, Nov. 22, 2024 NEW YORK, Nov. 22, 2024 /PRNewswire/ -- The Gross...
November 25, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against MGX PR Newswire NEW YORK, Nov. 21, 2024 NEW YORK, Nov. 21, 2024 /PRNewswire/ -- The Gross Law Firm issues...
Investors who lost money on Metagenomi, Inc.(MGX) should contact The Gross Law Firm about pending Class Action - MGX PR Newswire NEW YORK, Nov. 18, 2024 NEW YORK, Nov. 18, 2024 /PRNewswire/...
Class Action Filed Against Metagenomi, Inc. (MGX) Seeking Recovery for Investors - Contact The Gross Law Firm PR Newswire NEW YORK, Nov. 14, 2024 NEW YORK, Nov. 14, 2024 /PRNewswire/ -- The Gross...
Initiating IND-enabling activities for MGX-001 development candidate (DC) in hemophilia A; Achieved durable Factor VIII activity levels over twelve months in nonhuman primate (NHP) study On track...
Shareholders that lost money on Metagenomi, Inc.(MGX) should contact The Gross Law Firm about pending Class Action - MGX PR Newswire NEW YORK, Nov. 11, 2024 NEW YORK, Nov. 11, 2024 /PRNewswire/...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.58 | 18.0124223602 | 3.22 | 4.4 | 3.22 | 2129432 | 3.97931551 | CS |
| 4 | 1.78 | 88.1188118812 | 2.02 | 4.92 | 1.83 | 5324594 | 4.0123961 | CS |
| 12 | 1.77 | 87.1921182266 | 2.03 | 4.92 | 1.61 | 1886944 | 3.72505077 | CS |
| 26 | 0.09 | 2.42587601078 | 3.71 | 5.4999 | 1.61 | 957908 | 3.64812692 | CS |
| 52 | -6.45 | -62.9268292683 | 10.25 | 12.74 | 1.61 | 614982 | 4.25273278 | CS |
| 156 | -6.45 | -62.9268292683 | 10.25 | 12.74 | 1.61 | 614982 | 4.25273278 | CS |
| 260 | -6.45 | -62.9268292683 | 10.25 | 12.74 | 1.61 | 614982 | 4.25273278 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
